The Experts below are selected from a list of 15 Experts worldwide ranked by ideXlab platform
Kyogo Itoh - One of the best experts on this subject based on the ideXlab platform.
-
Expression of the tumor‐rejection Antigen SART1 in brain tumors
International journal of cancer, 1999Co-Authors: Toshihiro Imaizumi, Terukazu Kuramoto, Kazuko Matsunaga, Shigeki Shichijo, Shigeru Yutani, Minoru Shigemori, Koutaro Oizumi, Kyogo ItohAbstract:We have reported a tumor-rejection Antigen, SART1(259), possessing tumor epitopes capable of inducing cytotoxic T lymphocytes (CTLs) in epithelial-cancer patients. This study investigated the expression of SART1(259) Antigen in brain tumors, to explore for a potential molecule for use in specific immunotherapy of patients with brain tumors. The SART1(259) Antigen was detected in the cytosol fraction of 13 of 18 (72%) glioma cell lines and in 12 of 34 (35%) brain-tumor tissues, with a higher rate of expression among malignant gliomas (5/10, 50%) and schwannomas (3/4). HLA-A24-restricted and SART1-specific CTLs recognized the HLA-A24+ and SART1(259)+ glioma cells, and the levels of recognition correlated both with HLA-A24-Antigen expression level and with the concentration of the SART1 peptide Antigen. Therefore, the SART1(259) Antigen could be a target molecule for specific immunotherapy of patients with brain tumors expressing HLA-class-1 Antigens.
Toshihiro Imaizumi - One of the best experts on this subject based on the ideXlab platform.
-
Expression of the tumor‐rejection Antigen SART1 in brain tumors
International journal of cancer, 1999Co-Authors: Toshihiro Imaizumi, Terukazu Kuramoto, Kazuko Matsunaga, Shigeki Shichijo, Shigeru Yutani, Minoru Shigemori, Koutaro Oizumi, Kyogo ItohAbstract:We have reported a tumor-rejection Antigen, SART1(259), possessing tumor epitopes capable of inducing cytotoxic T lymphocytes (CTLs) in epithelial-cancer patients. This study investigated the expression of SART1(259) Antigen in brain tumors, to explore for a potential molecule for use in specific immunotherapy of patients with brain tumors. The SART1(259) Antigen was detected in the cytosol fraction of 13 of 18 (72%) glioma cell lines and in 12 of 34 (35%) brain-tumor tissues, with a higher rate of expression among malignant gliomas (5/10, 50%) and schwannomas (3/4). HLA-A24-restricted and SART1-specific CTLs recognized the HLA-A24+ and SART1(259)+ glioma cells, and the levels of recognition correlated both with HLA-A24-Antigen expression level and with the concentration of the SART1 peptide Antigen. Therefore, the SART1(259) Antigen could be a target molecule for specific immunotherapy of patients with brain tumors expressing HLA-class-1 Antigens.
Terukazu Kuramoto - One of the best experts on this subject based on the ideXlab platform.
-
Expression of the tumor‐rejection Antigen SART1 in brain tumors
International journal of cancer, 1999Co-Authors: Toshihiro Imaizumi, Terukazu Kuramoto, Kazuko Matsunaga, Shigeki Shichijo, Shigeru Yutani, Minoru Shigemori, Koutaro Oizumi, Kyogo ItohAbstract:We have reported a tumor-rejection Antigen, SART1(259), possessing tumor epitopes capable of inducing cytotoxic T lymphocytes (CTLs) in epithelial-cancer patients. This study investigated the expression of SART1(259) Antigen in brain tumors, to explore for a potential molecule for use in specific immunotherapy of patients with brain tumors. The SART1(259) Antigen was detected in the cytosol fraction of 13 of 18 (72%) glioma cell lines and in 12 of 34 (35%) brain-tumor tissues, with a higher rate of expression among malignant gliomas (5/10, 50%) and schwannomas (3/4). HLA-A24-restricted and SART1-specific CTLs recognized the HLA-A24+ and SART1(259)+ glioma cells, and the levels of recognition correlated both with HLA-A24-Antigen expression level and with the concentration of the SART1 peptide Antigen. Therefore, the SART1(259) Antigen could be a target molecule for specific immunotherapy of patients with brain tumors expressing HLA-class-1 Antigens.
Kazuko Matsunaga - One of the best experts on this subject based on the ideXlab platform.
-
Expression of the tumor‐rejection Antigen SART1 in brain tumors
International journal of cancer, 1999Co-Authors: Toshihiro Imaizumi, Terukazu Kuramoto, Kazuko Matsunaga, Shigeki Shichijo, Shigeru Yutani, Minoru Shigemori, Koutaro Oizumi, Kyogo ItohAbstract:We have reported a tumor-rejection Antigen, SART1(259), possessing tumor epitopes capable of inducing cytotoxic T lymphocytes (CTLs) in epithelial-cancer patients. This study investigated the expression of SART1(259) Antigen in brain tumors, to explore for a potential molecule for use in specific immunotherapy of patients with brain tumors. The SART1(259) Antigen was detected in the cytosol fraction of 13 of 18 (72%) glioma cell lines and in 12 of 34 (35%) brain-tumor tissues, with a higher rate of expression among malignant gliomas (5/10, 50%) and schwannomas (3/4). HLA-A24-restricted and SART1-specific CTLs recognized the HLA-A24+ and SART1(259)+ glioma cells, and the levels of recognition correlated both with HLA-A24-Antigen expression level and with the concentration of the SART1 peptide Antigen. Therefore, the SART1(259) Antigen could be a target molecule for specific immunotherapy of patients with brain tumors expressing HLA-class-1 Antigens.
Shigeki Shichijo - One of the best experts on this subject based on the ideXlab platform.
-
Expression of the tumor‐rejection Antigen SART1 in brain tumors
International journal of cancer, 1999Co-Authors: Toshihiro Imaizumi, Terukazu Kuramoto, Kazuko Matsunaga, Shigeki Shichijo, Shigeru Yutani, Minoru Shigemori, Koutaro Oizumi, Kyogo ItohAbstract:We have reported a tumor-rejection Antigen, SART1(259), possessing tumor epitopes capable of inducing cytotoxic T lymphocytes (CTLs) in epithelial-cancer patients. This study investigated the expression of SART1(259) Antigen in brain tumors, to explore for a potential molecule for use in specific immunotherapy of patients with brain tumors. The SART1(259) Antigen was detected in the cytosol fraction of 13 of 18 (72%) glioma cell lines and in 12 of 34 (35%) brain-tumor tissues, with a higher rate of expression among malignant gliomas (5/10, 50%) and schwannomas (3/4). HLA-A24-restricted and SART1-specific CTLs recognized the HLA-A24+ and SART1(259)+ glioma cells, and the levels of recognition correlated both with HLA-A24-Antigen expression level and with the concentration of the SART1 peptide Antigen. Therefore, the SART1(259) Antigen could be a target molecule for specific immunotherapy of patients with brain tumors expressing HLA-class-1 Antigens.